Thales Partners with DAS in Fully Supporting Hong Kong International Airport's Three-Runway System Expansion Project
5.8.2021 05:00:00 EEST | Business Wire | Press release
Thales and Dah Chong Hong – Dragonair Airport GSE Service Ltd. (DAS) announced that they have been selected by the Civil Aviation Department (CAD) of the Hong Kong Special Administrative Region Government through global open tender exercise to deploy the new Instrument Landing System (ILS) and to support the Three-runway System (3RS) expansion project at the Hong Kong International Airport (HKIA). This leading solution will largely help HKIA further improve the capacity and efficiency of aircraft landing while maintaining the highest standard of flight safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005024/en/
© Hong Kong International Airport
The six sets of new ILS to be installed at the HKIA under 3RS will make use of Thales state-of-the-art technologies. The new ultra-wide aperture localizer array with 32-element localizer antenna will provide highly accurate guidance signals to aircraft approaching and landing on the runway in all weather conditions, day and night, allowing the safest and the most efficient aircraft landing at the HKIA while requiring less equipment safeguarding area.
The new ILS will also support selected runways with Category III operations including Low Visibility Operations (LVO) under foggy/heavy rain conditions. The whole Thales solution has already been deployed at various major international airports, such as Istanbul New Airport and Ankara Esenboga Airport in Turkey as well as Paris Charles De Gaulle Airport in France.
In Hong Kong, Thales has been supporting HKIA with superior products and technologies over the past 20 years as it has grown and become one of the busiest regional and international aviation hub. With HKIA stepping up its capacity to cater for the increasing demand of air traffic growth, Thales, as one of the most trusted partners of CAD, will once again contribute to “one of the largest infrastructure projects in Hong Kong’s history”.
“We are proud to have been selected by the Civil Aviation Department under global open tender as the supplier of new ILS for the HKIA, which is one of the key systems with proven international reference and reliability performance to support operations on the runway. This new selection strengthens our position as a proven airspace solutions provider in Asia and makes HKIA a world reference in terms of navigation aids equipped airport. I am sure the knowledge and experience that Thales is bringing to the project will ensure smooth and reliable operations at the HKIA during aircraft landing.” Mr. Kais MNIF, Navigation and Non-radar Surveillance Global Business Director, Thales.
“We are also delighted to work together with Thales as the local partner for the ILS solution. This project will leverage the strength and expertise of both companies to jointly deliver a world-class critical air navigation service equipment to CAD at the Hong Kong International Airport.” Angel Cheung, General Manager, Dah Chong Hong – Dragonair Airport GSE Service Ltd.
DAS is responsible for the project liaison and coordination with various stakeholders, overall logistic support, and on-site installation of this advanced ILS project. Thales together with DAS, commit to ensuring on-time and satisfying delivery of the solution to the CAD. Both companies have cooperated on several aviation projects to cater for future aviation traffic growth in the region, which will definitely further accelerate the on-going development in the Guangdong-Hong Kong-Macau Greater Bay Area.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About Thales in China
Thales provides innovative solutions for the infrastructure that forms the backbone of China’s growth. The Group has been present in China for more than 40 years and is the trusted partner for the Chinese aviation and urban rail transportation industries. In the meanwhile, from secure software to biometrics and encryption, Thales has successfully applied its advanced technology to mobile communication, banking, IoT and software monetization etc. Thales has 3 JVs and employs 2,100 people with offices located in 7 cities in China. Thales established R&D centers and Innovation Hubs in Beijing, Dalian and Hong Kong to provide innovative solutions for both China and international market.
About Dah Chong Hong – Dragonair Airport GSE Service Ltd.
Dah Chong Hong –Dragonair Airport GSE Service Ltd. (“DAS”), a subsidary of Dah Chong Hong Holdings established in 1996, is an aviation support service provider with operations in Hong Kong and mainland China. DAS provides a wide array of professional services for the global aviation industry including supply, development and implementation of airport special system as well as design, supply, maintenance, leasing and fleet management of aviation and airport ground support equipment.
About Dah Chong Hong Holdings
Dah Chong Hong Holdings, an indirect wholly owned subsidiary of CITIC Limited (stock code: 0267.HK), is an integrated trading and distribution company operating in Asia, supported by an extensive logistics network. DCH is a leading distributor and dealer of motor vehicles in Greater China as well as a provider of a full range of associated services. DCH’s consumer business comprises the manufacture, retail and distribution of food, healthcare, electrical appliances, beauty and lifestyle products. DCH employs over 16,500 staff with operations in 12 Asian markets.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005024/en/
Contact information
PRESS
Thales, Media relations
Civil aerospace
Maria Mellouli
+33 (0)6 89 73 25 47
maria.mellouli@thalesgroup.com
Thales in China
Head of Government Affairs & Communications
Tammy Qiu
+86 10 65875066
tammy.qiu@asia.thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 15:40:00 EEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 15:30:00 EEST | Press release
ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes. The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every aspect of well delivery through a technology-enabled operating model. It combines digital drilling workflows with au
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom